Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
EPRX.TOthis companyEupraxia Pharmaceuticals Inc.	CA$10.34	-9.83×	5.04×	0×	-8.54×	-78.4%	0.0%	0.0%	0.0%	-47.9%	-48.6%	-7.2%	0×	2.07×	0×	15.12×	0.0%	2	34.16	2	C
CYBN.NECybin Inc.	CA$12.78	-1.59×	1.01×	0×	-0.54×	-62.3%	0.0%	0.0%	0.0%	-63.2%	-60.9%	-57.1%	0×	1.11×	-48.88×	9.52×	0.0%	3	8.63	2	C
DR.TOMedical Facilities Corporation	CA$15.34	10.6×	2.99×	0.87×	3.81×	67.8%	38.0%	18.4%	8.2%	28.0%	19.5%	18.2%	0.78×	0.24×	13.23×	1.79×	2.3%	8	2.15	4	A
HBP.TOHelix BioPharma Corp.	CA$0.90	-34.09×	8.05×	0×	-32.25×	-104.3%	0.0%	0.0%	0.0%	-23.6%	-19.7%	-3.8%	0.29×	-0.92×	-20.22×	0.19×	0.0%	1	-7.69	1	D+
MDNA.TOMedicenna Therapeutics Corp.	CA$0.44	-2.91×	21.45×	0×	-1.99×	-91.3%	0.0%	0.0%	0.0%	-741.7%	-725.4%	0.0%	0.05×	0.26×	0×	1.52×	0.0%	0	-30.04	2	C
OGI.TOOrganigram Global Inc.	CA$1.26	-14.84×	1.03×	1.39×	-13.88×	-3094.3%	3.7%	-34.1%	-9.6%	-7.1%	-13.0%	-6.8%	0.03×	3.64×	0×	2.26×	0.0%	5	-0.07	4	A
Peer median	—	-2.91×	2.99×	0×	-1.99×	-91.3%	0.0%	0.0%	0.0%	-23.6%	-19.7%	-3.8%	0.05×	0.26×	0×	1.79×	0.0%	3	-0.07	2	—